Drug intelligence / Profile preview

RJB-c1110

Development stage: Preclinical
Lead developer: Rejuvenate Bio
Modality: Gene Therapies
Administration: Parenteral

Overview

RJB-c1110 is a discovery-stage gene therapy candidate developed by Rejuvenate Bio, primarily targeting the animal health market. The company specializes in developing gene therapies to treat chronic, age-related diseases by addressing systemic drivers of aging. While the specific therapeutic targets and indications for RJB-c1110 remain undisclosed, it is part of a pipeline that utilizes viral vectors to deliver genes intended to reverse or mitigate age-associated pathologies. The program is currently listed as being in discussions for multiple veterinary indications.

Beyond the preview

Go deeper on RJB-c1110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJB-c1110.

Explore the full profile